EASME

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Brevel has developed an innovative cultivation technology focused on the sustainable and cost-effective production of microalgae. Utilizing high-tech, fully automated indoor systems that feature internal illumination, Brevel's approach achieves significant cost reductions and substantially higher yields compared to traditional methods. This advanced technology positions the company to tap into various markets in need of microalgae-derived products, including sustainable food, materials, chemicals, pharmaceuticals, and energy. By unlocking the full potential of microalgae, Brevel aims to create an alternative protein source suitable for mass production, addressing the increasing demand for environmentally friendly solutions across multiple industries.

InterAx is pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health. InterAx is a Swiss biotech company, spinoff of ETH Zurich and Paul Scherrer Institute incorporated in 2016, reinventing drug discovery to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases. Our solution lies in the combination of in-house experimental assays, mathematical modelling and artificial intelligence to analyze and predict the physiological response of cells to drugs. We are able to describe the complex action of drug molecules in their cellular context and to guide the optimization of drug candidates to achieve a specific cellular response leading to higher efficacy and reduced side effects in humans, thus significantly accelerating drug discovery and de-risking clinical trials.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Eden Microfluidics is a young innovative company founded in 2017. The company aims to provide advanced and certified materials, microfabrication and microfluidics solutions to both researchers and industrial partners. Eden Microfluidics is driven by a team of talented and passionate scientists, innovators and entrepreneurs, thriving to develop radical microfluidic solutions, for biomedical to environmental challenges. All together, they assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems. Eden Microfluidics is here to offer you access to the latest, up-to-date microfluidic science and technology.

Altar is a biotechnology company focused on automated fluidics, dedicated to enhancing the performance of microorganisms for commercial applications. They develop proprietary technologies that utilize automated cultivation devices to harness natural selection, allowing for the continuous and contamination-free proliferation of cell suspensions. This innovative approach enables industries to improve the efficacy of microorganisms used in producing food, feed, flavors and fragrances, cosmetics, fuels, chemicals, and health products. By ensuring 24/7 operation, Altar's technology supports the long-term cultivation of microbes, making it a valuable resource for various sectors seeking to optimize their microbial applications.

Calyxia specializes in the design and production of customizable, biodegradable microcapsules that protect active ingredients during industrial processes. These microcapsules, which range in size from one micron to 50 microns, are engineered to safeguard ingredients from degradation while ensuring their timely and targeted release. This innovative approach enhances the performance of formulations while promoting environmental sustainability by enabling the creation of products with fewer ingredients and improved efficacy. Calyxia's solutions cater to various industries, including advanced materials, sustainable agriculture, and home care, allowing companies to develop newly formulated products that meet modern performance and environmental standards.

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

FreezeM is focused on advancing preservation technologies that enhance the use of insects as a sustainable protein source for the animal feed industry. The company is developing innovative methods for large-scale freezing of insects, which will facilitate the creation of global stocks of frozen insect neonates and eggs. This approach aims to address critical challenges related to the availability, cost, and regulatory hurdles associated with utilizing insects in animal feed. By ensuring a stable and year-round production of these beneficial insects, FreezeM seeks to make a significant impact on the animal feed market, while also contributing to biological pest control and species preservation.

Toleranzia develops drugs that utilize the immune system's own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the disease cause, can cure or greatly alleviate the disease and not just reduce the symptoms that current treatments do. The company's drug candidate, TOL2, is developed for the autoimmune nerve and muscle disease myasthenia gravis.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Surflay Nanotec focuses on functional surfaces, nanoscale coatings, polymers and microsensors. Their aim at Surflay is to rapidly deliver product-oriented scientific solutions to their customers and partners. They offer four inter-connected services: Contract research and surface solutions: surface modification and functionalization, Layer-by-Layer (LbL) coatings Fluorescent labeled polymers Nanostructures / Microstructures / Beads Microsensors: bioanalysis, pH, temperature & more

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

WeedOut is a biotechnology company dedicated to developing innovative weed control solutions. The company focuses on creating bio-herbicides that utilize a unique approach to combat resistant weeds. By employing weed pollen and applying it during the flowering period through artificial pollination, WeedOut's products prevent the generation of viable seeds from these resistant weeds. This method aims to reduce reliance on toxic herbicides and minimize the application of higher herbicide doses, offering a natural alternative for farmers and stakeholders in the agricultural sector to effectively manage weed populations.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art mass spectrometry based methodologies.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

PlumeSTARS is an innovative PMI specialized in drug delivery to lung for the treatment of respiratory diseases.

Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guided regeneration of soft tissues and bone.

Planktovie develops and markets nutritional solutions that meet the highest standards for the maintenance of aquatic organisms.

AMF Medical is focused on developing Sigi, an innovative patch pump designed to administer insulin with exceptional ease of use. This novel device is intended for seamless integration into closed loop systems, compatible with third-party Continuous Glucose Monitoring products and dose-calculating algorithms. The company's mission is to alleviate the therapy burden faced by individuals with diabetes, ultimately aiming to enhance their quality of life. AMF Medical was established in early 2021 as a spin-off from Advanced Microfluidics, which specializes in high-end lab equipment components that utilize related technologies.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

ChemoTech is a Scandinavian company based at Medicon Village in Lund, Sweden. The company’s founders have extensive experience of cancer treatment through surgical oncology and clinical development. The company is dedicated to using its unique patented know-how to develop innovation in cancer care through genuine research and clinical trials.

Scandion Oncology A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing treatments for chemotherapy resistance in cancer patients. Founded in 2017, the company is advancing its lead product, SCO-101, which is currently undergoing Phase II clinical trials for breast and colorectal cancers. Additionally, it is working on SCO-201, a product in late pre-clinical development aimed at treating solid tumors. Scandion Oncology collaborates with the University of Copenhagen to co-develop SCO-301, a candidate designed to reverse drug resistance, and has partnered with Per Norlén to investigate the combined anti-tumor effects of mitazalimab and SCO-101 in resistant tumor models. The company's mission is to enhance treatment outcomes and quality of life for cancer patients who experience chemotherapy resistance, addressing a significant challenge in oncology where nearly half of patients do not respond to chemotherapy.

Martin and Co Ltd was funded, for providing different R&D services in the field of chemistry method development, biotechnological process development and analytical chemistry method developments. Their company is located at Berlini Park (http://www.berlinipark.hu/), which is an incubation space for chemistry related start-ups in Budapest (formal buildings of Medicinal Chemistry research Center, which was shut down 10 years ago). We have all necessary laboratory units, toolkits and devices to carry out their research. Regarding analytical chemistry, we have Shimadzu Mass Spectrometer-2020(CL) and excess to other analytical units at the campus of Berlini Park. In summer of 2017, after the completion of RAID SME Instrument Phase 1 project by Tonosoft Ltd, the RAID knowledge and rights were transferred to Martin and Co Ltd. The patent about RAID project was prepared and submitted by Martin and Co Kft in October 2017.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Brain Stimulation AB is a Swedish SME started in 2011 with the aim to provide an efficient assessment and rehabilitation after stroke and traumatic brain injuries. Exploiting brain plasticity results from research within a new concept of rehabilitation and diagnosis of cognitive impairments and disability of attention in stroke patients (Spatial Neglect). They address the global challenge of rehabilitating need for cognitive and upper limb impairments from Stroke, Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases by using Enriched Rehabilitation.

BIOsens Inc. specializes in developing biosensors for the rapid quantitative diagnostics of food toxins, particularly mycotoxins. The company offers a testing device that allows for easy sample preparation and delivers results within 15 minutes. These results are stored in the cloud, utilizing Internet of Things (IoT) technology. By providing efficient and reliable testing solutions, BIOsens aims to enhance food safety and help consumers trust the safety of their food products.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Probiomedica combines engineering, biology, photonics and robotics, and aims to develop innovative devices for the application to health and personal care.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

Surgitate fabricates synthetic models that surgeons, medical and veterinary students, and other medical staff such as nurses and obstetricians can practice on. Their models are designed to create a realistic feel of incision, dissection, and suturing. Their cofounders are a materials engineer (Ozge Akbulut, PhD) and a thoracic surgeon (Barkın Eldem, MD). Surgitate has two investors: Farplas, leading plastic automotive parts manufacturer in Turkey, and Inovent, Turkey’s first technology commercialization/accelerator and seed funding company. They rely on expertise of Farplas in process development, molding, and painting for the mass scale production of synthetic body parts. Inovent assures that we are well-connected to our potential investors and customers; and handles business and marketing plans.

MycoSolutions AG specializes in developing customized soil additives designed to protect and maintain trees, particularly veteran specimens. Based in St. Gallen, Switzerland, the company offers a range of services including the diagnosis of fungal pathogens, visual tree inspections, hazard assessments, and the development of tailor-made plant growth promoters. MycoSolutions is recognized as a technology leader in the efficient use of mushrooms, leveraging the expertise of its founders and employees to provide environmentally friendly alternatives to conventional wood preservatives and agricultural pesticides. The company's commitment to sustainability aims to reduce the environmental impact of harmful chemicals, while its educational initiatives include training sessions and publications to enhance knowledge in tree care and soil health.

SagaNatura is a dynamic Icelandic biotech company, located in one of the most pristine environments on earth – Iceland. SagaNatura focuses on development, production and export of health product from premium Icelandic ingredients. SagaNatura is a leading Icelandic dynamic biotech company, located in one of the most pristine environments on earth – Iceland. SagaNatura‘s focuses on and produces the Icelandic pure, natural form the wild growing organic herb Archangelica Angelica and high-quality Astaxanthin. SagaNatura offers consumer products Icelandic origin that is high quality, safe and vegan-friendly. SagaNatura has two major brands, SagaMedica (est. 2000) and KeyNatura (est. 2014).

Ecohelix specializes in the production of innovative amphiphilic polymers derived from lignocellulosic side streams of the pulp industry. Utilizing a patented enzymatic process, the company transforms residual materials such as lignin and hemicellulose into high-performance, biodegradable polymers. Their flagship product, WOODMER®, serves as a sustainable alternative to conventional plastics and fossil-based materials, finding applications in packaging, adhesives, and paper chemicals. By harnessing underutilized raw materials, Ecohelix not only enhances the value of the pulp industry but also contributes to a more sustainable future by significantly reducing CO2 emissions and promoting environmentally friendly practices across various sectors, including packaging, construction, and cosmetics.

CLOVER Bioanalytical Software is a bioinformatics company specialized in data processing for Bioanalytical Chemistry and Microbial ID and other clinical diagnostics applications using mass spectrometry. Formed by a group of Ph.D. graduates with a wide expertise in business and research, it brings a perfect match to develop cutting-edge software and statistical analysis projects in the biomedical field. They are specialized in mass spectrometry, its clinical applications and mass spectrometry imaging. But their expertise cover many more applications, like medical image processing, univariate and multivariate statistical analysis, and Big Data. They are truly customer-oriented, keeping in mind the goals of their clients and the scalability of the systems. They count with experts in biomedicine, chemistry and biotechnology that speak your own language and understands your needs.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

Mimetis Biomaterials SL is a Barcelona-based company that specializes in designing and manufacturing biomimetic bone graft substitutes for various medical applications, including dental, craniomaxillofacial, and orthopedic sectors. Founded in 2013, Mimetis focuses on creating synthetic solutions that closely mimic the properties of natural bone to address specific patient needs. The company offers a range of products, including biomimetic granules for filling bone defects, as well as services such as original equipment manufacturing, consulting, and co-development. With over 15 years of research backing its innovations, Mimetis has secured more than 2.5 million euros in public grants and funding to support its growth. The company is currently seeking additional funding to expand its commercial presence in orthopedics and to launch its advanced 3D-printed biomimetic solutions, aimed at improving patient outcomes in complex cases.

Double Bond Pharmaceutical is a pharmaceutical company focused on developing and commercializing innovative treatments for cancers, infections, autoimmune diseases, and other life-threatening conditions. The company aims to address unmet medical needs by providing more efficient and safer therapeutic options for patients. Through its first-in-class approaches, Double Bond Pharmaceutical seeks to improve patient outcomes and contribute significantly to the healthcare market.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Medfield Diagnostics AB, founded in 2005 by Mikael Persson and Andreas Fhager, specializes in the development and commercialization of diagnostic instruments utilizing microwave technology. The company focuses on advancing stroke diagnostics through its innovative products, including Strokefinder and Impending Applications. By leveraging promising research conducted at Chalmers University of Technology, Medfield Diagnostics aims to enhance the accuracy and efficiency of stroke detection and management.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

TomoWave commercializes and produces innovative imaging modalities with applications in clinical medicine and preclinical research. Our proprietary technology “listens to the sound of light” to produce highly resolved images from the depth of tissues. The main targeted medical needs of TomoWave platform technology include detection and diagnostics of cancer, image guided interventions and monitoring the effectiveness of anticancer therapy and diagnostics imaging of vascular and blood related conditions. A pipeline of innovative optoacoustic and laser ultrasonic imaging technologies based on inventions made by the company founder, Dr. Alexander Oraevsky, pioneer of biomedical optoacoustics and recipient of multiple grants and awards for development of molecular imaging systems and applications. TomoWave Laboratories has the capability to generate intellectual property and develop its IP from idea to validated clinical prototypes and brings these technologies to the market place through regulatory certification.

Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients. Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.

FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.

Seaweed Solutions AS is a seaweed cultivator and innovator established in 2009, focusing on large-scale ocean farming of seaweed for various applications, including food, feed, pharmaceuticals, and biomaterials. The company has established itself as a leader in European seaweed cultivation, controlling the entire value chain from proprietary seed hatcheries to processing plants. With a patented cultivation technology called Seaweed Carrier, Seaweed Solutions combines extensive knowledge in marine biology and engineering to pioneer modern seaweed farming practices. Its primary operations are based in Norway, where it manages the largest seaweed farms in Europe dedicated to brown macroalgae. The company's objectives include becoming the leading supplier of cultivated biological seaweed and seaweed seeds in Europe. Additionally, Seaweed Solutions forms partnerships and offers turnkey solutions related to cultivation technology, raw material sourcing, market development, and environmental services, thereby supporting sustainable practices in the seaweed industry.

High value polysaccharides and pigments produced with high-output micro-algae and vertical photo-reactors.

TransCure bioServices has developped unique Research & Development (R&D) platforms, called the Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. They provide access to these platforms as a fee-for-service for the pharmaceutical companies, biotechs as well as academic laboratories which profile new drugs targeting immuno-related diseases and novel anti-HIV/AIDS therapies.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

ProtectPipe is a Finnish microbiotechnology company producing an innovative microbe solution that removes organic waste from drainpipes. The microbe solution moves to the areas with build-up in the pipes and devours the waste. That is an ecological way to stop the erosion in pipes and prevent any harmful waste from entering the fragile environment.

BIA doo has consulting sales and technical support in the fields of biotechnology, chromatography, organic synthesis, sample preparation, laboratory equipment, and software for laboratories. It is a supplier of laboratory and process equipment.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

High Efficiency Water Condensing Biomembranes.ThinAir is tackling one of the three biggest problems on the planet, water scarcity. ThinAir has developed a bio-membrane that condenses water from air efficiently and energy-free. Inspired by the potential of biomimicry,they've harnessed the way beetles capture water even in the driest habitats in the world. The technology will facilitate agriculture and provide clean water for human consumption in areas where clean water is scarce.

Vetbiobank is a biotech company specializing in veterinary regenerative medicine. The company develops cell and tissue therapies aimed at enhancing animal health and care. In addition to its focus on veterinary applications, Vetbiobank also engages in human cellular and tissue therapies. It supplies veterinarians with clinical-grade cell and tissue products, thereby supporting medical and scientific needs within the veterinary field. Through its innovative approach, Vetbiobank aims to improve outcomes for animals by advancing regenerative medicine techniques.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.

Pila Pharma AB is a clinical stage biotech company based in Malmö, Sweden, focused on developing XEN-D0501, a potent and selective TRPV1 antagonist. This molecule is being investigated as a treatment for type 2 diabetes, obesity, and the rare and painful condition erythromelalgia. XEN-D0501 has undergone testing in approximately 300 subjects across phase 1 and 2 trials, demonstrating a favorable safety profile in both healthy volunteers and patients with various conditions, including type 2 diabetes. The compound has shown efficacy in improving glucose-stimulated insulin secretion in type 2 diabetics. Recent preclinical safety studies for XEN-D0501 have been completed without adverse effects, allowing the company to advance to clinical trials lasting up to three months. In July 2022, Pila Pharma received US Orphan Drug Designation for XEN-D0501 for its application in treating erythromelalgia.

Vetherapy is a biotech company established in 2015, specializing in veterinary regenerative medicine and tissue engineering. The company develops innovative products utilizing stem cells, platelet-rich plasma (PRP), and biomaterials to address various animal health conditions. Vetherapy focuses on ensuring quality and safety in the processes of stem cell isolation, expansion, and cryopreservation, as well as in the extraction of plasma rich in growth factors. By providing access to a stem cell and PRP bank through their cryopreservation services, Vetherapy ensures that these vital therapeutics are readily available for immediate veterinary use. Their therapies promote tissue regeneration, enhance overall physical condition, and facilitate faster healing in animals, addressing a range of clinical needs effectively.

RemAb Therapeutics is a developer of polymeric glycoconjugates molecule designed to remove antibodies and treat nosocomial infections. The company's technology aims to develop polymeric glycoconjugates to eliminate non-neutralizing natural antibodies that interfere with the natural response of the immune system and favor pathogen growth, providing patients with a new way of treating and preventing various pathologies.

PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

NapiFeryn BioTech specializes in extracting protein from waste streams generated during rapeseed oil production. The company employs innovative biorefinery technology that enables a more sustainable and efficient extraction process compared to traditional methods. This approach results in high-quality protein isolates and concentrates that serve as functional and nutritional alternatives to animal-derived proteins. NapiFeryn's products are versatile and can be utilized in a variety of applications, catering to the needs of oil mills and food producers seeking to develop sustainable bio proteins.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Nanografi, established in 2011 at METU Technopolis, has been at the forefront of graphene production, advanced materials and nanotechnology. In 2020, Nanografi launched the most efficient and largest graphene mass production facility, making it one of the pioneering companies in the world. For over a decade, Nanografi has remained a powerful solution partner in advanced material technologies. Operating under Ahlatcı Holding, Nanografi is committed to innovation and anticipates the future's technological advancements and needs. Since 2011, leveraging its experience in high-tech solutions across more than 100 countries, Nanografi takes pride in contributing to thousands of valuable research studies and technologies, guided by its developed technologies and scientific investigations. Nanografi, a leading player in present and upcoming sectors like advanced material technologies, high-security authentication, biotechnology, and smart packaging technologies, remains committed to creating value with its international quality standards.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Immunitrack specializes in an AI-based prediction and assessment platform aimed at supporting biotechnology and pharmaceutical companies. The company provides contracted research services that focus on predicting immune system reactions to various pharmaceuticals. By producing reagents for examining these immune responses, Immunitrack assists clients in the development of biologics and vaccines. Its work is instrumental in facilitating the creation of new therapeutic solutions within the pharmaceutical industry.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

NG Biotechnology is a biotechnology company established with long-term investments with the partnership structure of academicians who produce microbial cultures with years of experience in environmental biotechnologies and have worked on environmental and agricultural microbiology in established institutions abroad for many years.

Mercurna is a developer of life-changing mRNA medicines. They also develop modular nanomedicines that can be adapted to a multitude of diseases with ease. They built a sustainable business that keeps on providing society with truly valuable medicines. They also provide mRNA medicines particularly suited to the treatment of chronic inflammatory diseases.

Ahead Therapeutics is a biotech company focused on developing innovative treatments for various autoimmune disorders. Utilizing a proprietary technology centered on PS-liposomes that contain auto-autoantigens, the company aims to induce antigen-specific immune tolerance through a biomimetic process. This approach allows for the customization of encapsulated auto-antigens, targeting conditions such as Type 1 Diabetes, Multiple Sclerosis, and Celiac Disease. The technology is designed primarily as a reverse therapeutic vaccine, potentially offering permanent cures rather than just palliative care. Ahead Therapeutics' method boasts several advantages, including long-lasting effects, non-systemic immunosuppression, minimal toxicity, cost-effective production, and compatibility with other therapies. The effectiveness of this liposome-based platform has been validated in animal models, and preclinical non-regulatory assessments are underway for specific indications. The company plans to advance to preclinical regulatory stages and expand its treatment pipeline to address additional autoimmune conditions, recognizing the significant impact these diseases have on the global population and healthcare costs.

Bioengineering Laboratories (BEL) has been conceived as a young, streamlined and multi-faceted organization able to provide technical knowledge and a twenty year experience in designing, testing and producing innovative medical devices in the bioengineering industry. BEL is a pool of professional professionals able to critically address and re-elaborate the key aspects of a “modern” design in the medical field. The knowledge of the market, the openness to new clinical and surgical techniques, the curiosity towards new technologies, the application of an effective Quality System and the constant updating of the current legislative and regulatory requirements are their basis for engineering dedicated to life.

CyTuVax is a clinical stage vaccine company focused on developing innovative solutions to address significant medical needs. The company collaborates with leading European research institutions to advance its adjuvant technology, which enhances immune responses in both humoral and cellular aspects. This technology can be applied to both prophylactic vaccines targeting viral and bacterial pathogens and therapeutic vaccines for cancer treatment. By utilizing depot-attached cytokines as immune stimulators, CyTuVax's platform aims to improve the efficacy of standard vaccines, reduce the number of required injections, and ultimately place the patient at the center of its vaccine development efforts.

Chromition Limited, based in Manchester, United Kingdom, specializes in developing and supplying advanced nanoparticle solutions for various commercial applications. The company offers a range of products, including Luminspheres, which are multi-colored photoluminescent polymer nanoparticles used in bio-imaging, anti-counterfeiting, and lighting; Elecspheres, semiconductor polymer nanoparticle inks utilized in displays, electronics, lighting, solar cells, and sensors; and Dielecspheres, high-k dielectric films that allow electronic devices to function at ultra-low voltages and reduced power consumption. Founded in 2014, Chromition's technology originated at the University of Manchester and was spun out to facilitate the commercialization of innovative optoelectronic products.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

Chrysalix Technologies is an Imperial College spin-out company developing an innovative biomass fractionation process using low-cost ionic liquids. Currently, their society is heavily relying on the use of crude oil while products are discarded at the end of their lives. They want to change that, which is why they are developing novel chemical processes that enable us to live more sustainably in a clean world. Their first product is the BioFlex process that uses waste wood and agricultural by-products as well as sustainably grown biomass to produce a greener alternative to today’s petrochemical industry while providing unwanted waste materials with a new purpose.

IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative treatments for neurological disorders, particularly Parkinson’s disease. The company is advancing several drug candidates, including Mesdopetam, a dopamine D3 receptor antagonist, and IRL752, which targets postural dysfunction. Both compounds have successfully completed Phase IIa clinical trials. Additionally, IRLAB is exploring other research programs aimed at addressing neurodegenerative disorders and aging, such as IRL942, P001, and P003, which seeks alternatives to levodopa for Parkinson’s treatment. By focusing on the core dysfunctions associated with Parkinson’s disease and dementias, IRLAB aims to enhance the quality of life for patients suffering from these conditions. The company is headquartered in Gothenburg, Sweden.

Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.

ViewPoint is the precursor of behavioral tracking for zebrafish and rodents. Established in 1990, ViewPoint was the first to offer automated tracking of behavior for rodents. Our solutions give access to high throughput screening, reliable data, better time and cost efficiency and ground-breaking studies. Large-scale screening studies were previously prohibitively expensive and time-consuming, now with ViewPoint’s tools, research is driven forward at an unprecedented rate. There are many other advantages to automated behavioral tracking. Unlike manual observation, behaviors are recorded consistently each time, human uncertainty is excluded.

RegStem is an early stage biopharmaceutical company repurposing molecules and creating new treatments in the fields of regenerative medicine and more specifically in the areas of rare muscle and blood diseases with high unmet medical needs.

Numaferm GmbH, based in Düsseldorf, Germany, specializes in the production of peptides through an innovative bioprocess. Founded in 2017, the company has developed a reliable and cost-efficient manufacturing method that significantly reduces production costs, potentially by up to 1000 times. This process utilizes specially designed microorganisms that convert simple nutrients into peptides, creating a versatile platform capable of producing peptides regardless of their sequence, length, or functionality. Numaferm offers a range of services, including feasibility studies, custom synthesis, peptide development, and upscaling, supporting clients from the discovery phase to commercial production.

omicX decided to harness the exponentially growing collective intelligence in bioinformatics and to leverage it to exploit biological Big Data for novel applications in biotechnology, life science, medecine, agriculture and industry. Their fast-growing company has become a trusted leader and global reference in bioinformatics with users from world leading universities, medical institutions, pharmaceutical companies and the biotech industry.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Biprocel is a biotechnological company.

Biodentify was founded as a spin out from Dutch R&D group TNO, in December 2014. TNO is a 3000+ R&D organization, hosting the largest Microbiological research group in the Netherlands. It is owned and managed by JOA Ventures, 3 partners with extensive entrepreneurial experience bringing innovative technologies to market in the Oil & Gas industry. The company has developed a novel technology, predicting prospectivity before drilling, with approx. 70% accuracy, based on microbiological DNA analysis of shallow soil or seabed samples.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

MOGU is an Italian company focused on developing mycelium-based technologies to create sustainable products for interior design, emphasizing principles of the Circular Economy. Founded by Mycoplast, MOGU aims to research, develop, and commercialize a wide range of bio-materials, including bio-plastics made from mycelium and agro-industrial residues. This innovative approach utilizes the root structure of mushrooms to transform agricultural by-products into strong, functional composites that are fully natural and 100% compostable. MOGU's products cater to various markets, such as construction, packaging, and horticulture, and include materials that are lightweight, shock-absorbing, and resistant. By converting what is typically considered waste into valuable resources, MOGU seeks to disrupt traditional product design and promote ecological responsibility in material production.

SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.

Oxoprobics microplates provide a powerful tool and biological services based on this technology for obtaining proof of mechanism data, useful as first exploratory assessments, refocusing and adapting new tailored methodologies for its use in cell biology (e.g. mitochondrial inhibition or uncoupling, stimulation or inhibition of oxygen-consuming reactions catalyzed by enzymes, antibiotic resistance, etc.) or Immunology (lymphoproliferation kinetics in whole blood, antigen recognition and sensitivity, etc.).

In Ovo focuses on improving animal welfare and efficiency within the poultry industry by addressing the longstanding issue of culling one-day-old male chickens in hatcheries. The company has developed a biotechnological solution that employs biomarkers for gender screening early in the breeding process. This innovation eliminates the need for the stressful manual gender sorting currently in use, significantly reduces energy consumption and carbon dioxide emissions in hatcheries, and prevents the unnecessary killing of male chicks. By enhancing both the sustainability and efficiency of hatcheries, In Ovo aims to create a more humane approach to poultry production.